Recombinant C1-Inhibitor

@article{Relan2012RecombinantC,
  title={Recombinant C1-Inhibitor},
  author={Anurag Relan and Kamran Bakhtiari and Dr Edwin S. van Amersfoort and Joost C M Meijers and Cornelis Erik Hack},
  journal={BioDrugs},
  year={2012},
  volume={26},
  pages={43-52}
}
Recombinant human C1-inhibitor (rhC1INH; Ruconest®) has been developed for treatment of acute angioedema attacks in patients with hereditary angioedema (HAE) due to heterozygous deficiency of C1INH. Previous reports suggest that administration of plasma-derived C1INH products may be associated with an increased risk for thromboembolic complications. Our aim… CONTINUE READING